Cao Bianchuan, Liu Mei, Song Shaofang, Ding Ping, Huang Fuli, Huang Yongmao, Zou Yongsheng, Zhong Li
Department of Infectious Disease, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Department of Tuberculosis, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
AIDS Res Hum Retroviruses. 2025 Apr;41(4):203-210. doi: 10.1089/aid.2024.0001. Epub 2024 Dec 24.
This study focuses on women of childbearing age infected with HIV-1 in Liangshan Prefecture and analyses their HIV-1 RNA and HIV-1 DNA genotypic drug resistance to provide a theoretical basis and technical support for monitoring the spread of resistant strains and formulating and optimizing antiretroviral therapy regimens. The study subjects were women of childbearing age infected with HIV-1 who were followed up in the county of Liangshan Prefecture from January to September 2023. Peripheral venous blood samples were collected from each subject. The samples were centrifuged to separate the plasma and blood cells for HIV-1 RNA quantitative testing and HIV-1 genotypic drug resistance testing. A total of 47 participants were included in this study. When HIV-1 RNA were <50 copies/mL and between 50 and 1,000 copies/mL, the success rate of HIV-1 DNA gene amplification was significantly higher than that of HIV-1 RNA gene amplification. Among the 47 subjects, 17 (17/47, 36.17%) indicated successfully amplified HIV-1 RNA and HIV-1 DNA genotypic drug resistance in each region simultaneously, and 9 (9/17, 52.94%) developed any degree of resistance. Among these nine cases, five had consistent resistance, while four indicated inconsistent resistance. Among the five cases with identical drug resistance, there were three cases with inconsistent drug resistance mutations (DRMs). Among the four cases with inconsistent drug resistance results, one had DRMs at the HIV-1 DNA level but no DRMs at the HIV-1 RNA level, while the other three had more DRMs at the HIV-1 RNA level than at the HIV-1 DNA level. The combination of HIV-1 RNA and HIV-1 DNA genotypic drug resistance testing can improve the drawbacks of current single HIV-1 RNA genotypic drug resistance testing, especially when HIV-1 RNA is ≤1,000 copies/mL, and significantly improve the efficiency of HIV-1 genotypic drug resistance testing.
本研究聚焦于凉山州感染HIV-1的育龄女性,分析其HIV-1 RNA及HIV-1 DNA基因型耐药情况,为监测耐药毒株传播及制定和优化抗逆转录病毒治疗方案提供理论依据和技术支持。研究对象为2023年1月至9月在凉山州各县接受随访的感染HIV-1的育龄女性。采集每位研究对象的外周静脉血样本。将样本离心以分离血浆和血细胞,用于HIV-1 RNA定量检测及HIV-1基因型耐药检测。本研究共纳入47名参与者。当HIV-1 RNA<50拷贝/mL以及在50至1000拷贝/mL之间时,HIV-1 DNA基因扩增成功率显著高于HIV-1 RNA基因扩增成功率。在47名研究对象中,17名(17/47,36.17%)表明各区域HIV-1 RNA及HIV-1 DNA基因型耐药均成功扩增,其中9名(9/17,52.94%)出现了不同程度耐药。在这9例中,5例耐药一致,4例耐药不一致。在5例耐药相同的病例中,有3例耐药突变不一致。在4例耐药结果不一致的病例中,1例在HIV-1 DNA水平有耐药突变但在HIV-1 RNA水平无耐药突变,另外3例在HIV-1 RNA水平的耐药突变多于HIV-1 DNA水平。HIV-1 RNA与HIV-1 DNA基因型耐药检测联合应用可改善当前单一HIV-1 RNA基因型耐药检测的弊端,尤其是当HIV-1 RNA≤1000拷贝/mL时,可显著提高HIV-1基因型耐药检测效率。